A

n inactivated form of the poliovirus used to treat recurrent brain tumors is showing what researchers called encouraging long-term survival in a Phase 1 clinical trial published Tuesday.

The authors reported that 21 percent of patients were still alive three years after the recurrence of glioblastoma, an aggressive and quickly lethal form of brain cancer that is stubbornly resistant to treatment — even the new crop of immunotherapies have proven to be ineffective. Against that bleak backdrop, the early results suggest the experimental poliovirus therapy, invented at Duke Cancer Institute, has some promise.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy